Erratum: DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis (Modern Pathology (2006) 19 (1333-1338) DOI:10.1038/modpathol.3800654);DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis

Modern Pathology

Volumn 19, Issue 10, 2006, Pages 1333-1338

  Taylor, Nicholas P ^a,c   Zighelboim, Israel ^a   Huettner, Phyllis C ^a   Powell, Matthew A ^a   Gibb, Randall K ^a   Rader, Janet S ^a   Mutch, David G ^a   Edmonston, Tina B ^b   Goodfellow, Paul J ^a  

^a USA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinosarcoma; Clonality; DNA mismatch repair; Malignant mixed m llerian tumor; Microsatellite instability; TP53

Indexed keywords

DNA; PROTEIN MLH1; PROTEIN P53;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 17P; CLINICAL ARTICLE; FEMALE; GENE DELETION; GENETIC DISORDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS CARCINOMA;

EID: 33748853554     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800688     Document Type: Erratum

References (22)

1. Amant F, Cadron I, Fuso L, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005;98:274-280.
2. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
3. Callister M, Ramondetta LM, Jhingran A, et al. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 2004;58: 786-796.
4. Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990;14:317-328.
5. Emoto M, Iwasaki H, Kikuchi M, et al. Characteristics of cloned cells of mixed mullerian tumor of the human uterus. Carcinoma cells showing myogenic differentiation in vitro. Cancer 1993;71:3065-3075.
6. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997;57: 5379-5385.
7. Kounelis S, Jones MW, Papadaki H, et al. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29:82-87.
8. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990;9:1-19.
9. Abeln EC, Smit VT, Wessels JW, et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997;183:424-431.
10. Fujii H, Yoshida M, Gong ZX, et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000;60:114-120.
11. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 2003;100:5908-5913.
12. Amant F, Dorfling CM, Dreyers L, et al. Microsatellite instability in uterine sarcomas. Int J Gynecol Cancer 2001;11:218-223.
13. Risinger JI, Umar A, Boyer JC, et al. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Cancer Res 1995;55:5664-5669.
14. Taylor NP, Gibb RK, Powell MA, et al. Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. Gynecol Oncol 2006;100:107-110.
15. Kowalski LD, Mutch DG, Herzog TJ, et al. Mutational analysis of MLH1 and MSH2 in 25 prospectively-acquired RER+ endometrial cancers. Genes Chromosomes Cancer 1997;18:219-227.
16. Peiffer SL, Herzog TJ, Tribune DJ, et al. Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers. Cancer Res 1995;55:1922-1926.
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
18. Buttin BM, Powell MA, Mutch DG, et al. Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 2004;10:481-490.
19. Szukala SA, Marks JR, Burchette JL, et al. Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer 1999;9:131-136.
20. Abargel A, Avinoach I, Kravtsov V, et al. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer 2004;14:354-359.
21. Pijnenborg JM, van de Broek L, Dam de Veen GC, et al. TP53 overexpression in recurrent endometrial carcinoma. Gynecol Oncol 2006;100:397-404.
22. Mariani A, Sebo TJ, Katzmann JA, et al. Endometrial cancer: can nodal status be predicted with curettage? Gynecol Oncol 2005;96:594-600.